BPD

出典: meddic

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/01/21 16:34:32」(JST)

wiki ja

[Wiki ja表示]

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Asenapine in the treatment of borderline personality disorder: an atypical antipsychotic alternative.
  • Martín-Blanco A, Patrizi B, Villalta L, Gasol X, Soler J, Gasol M, Pascual JC.Author information aDepartment of Psychiatry, Santa Creu and Sant Pau Hospital bUniversitat Autònoma de Barcelona (UAB) cCentro de Investigación Biomédica en Red de Salud Mental, CIBERSAM dInstitut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Barcelona eBorderline Personality Disorder Unit, General de Catalunya Hospital, Sant Cugat, Spain.AbstractMany individuals with borderline personality disorder (BPD) receive medical treatment in clinical practice, although to date, there are no drugs specifically available for BPD. The recent Cochrane guideline suggests a benefit from using second-generation antipsychotics such as olanzapine or aripiprazole; nevertheless, side effects limit their use. Asenapine is a novel FDA-approved atypical antipsychotic for schizophrenia and bipolar disorder. However, it has not yet been tested for BPD. The goal of this observational open-label study was to assess the safety, tolerability and efficacy of asenapine in a series of cases of patients with BPD. Twelve individuals with BPD were recruited and treated with asenapine during an 8-week period. Eight individuals completed the study; a significant improvement was observed in the CGI-BPD (P<0.001) and BSL-23 (P<0.048) scales for BPD symptomatology. Besides, there was a significant improvement in the general psychopathology domains (BPRS, P<0.004), whereas no significant differences were observed in depressive symptoms. No serious adverse effects were reported and a significant weight reduction was observed (P=0.002). Asenapine appears to be a safe and effective agent in the treatment of patients with BPD, especially when other alternatives are not tolerated. These preliminary findings should be replicated in a controlled clinical trial.
  • International clinical psychopharmacology.Int Clin Psychopharmacol.2014 Mar;29(2):120-3. doi: 10.1097/YIC.0000000000000004.
  • Many individuals with borderline personality disorder (BPD) receive medical treatment in clinical practice, although to date, there are no drugs specifically available for BPD. The recent Cochrane guideline suggests a benefit from using second-generation antipsychotics such as olanzapine or aripipra
  • PMID 23962963
  • Early regular versus late selective poractant treatment in preterm infants born between 25 and 30 gestational weeks: a prospective randomized multicenter study.
  • Dilmen U, Ozdemir R, Tatar Aksoy H, Uras N, Demirel N, Kırimi E, Erdeve O, Ozer E, Baş AY, Gürsoy T, Zenciroğlu A, Ovalı F, Oğuz SS.Author information Zekai Tahir Burak Maternity and Teaching Hospital, Neonatal Intensive Care Unit , Ankara , Turkey .AbstractAbstract Objective: Surfactant treatment in the early hours of life significantly decreases the rates of death and air leak, and increases survival without bronchopulmonary dysplasia (BPD) in preterm infants. We aimed to compare the impact of early surfactant (ES) administration to late selective (LS) treatment on neonatal outcomes in preterm infants. Methods: All preterm infants between 25 and 30 wks gestational age and who were not entubated in the delivery room and did not have any major congenital malformation or perinatal asphyxia were randomized to ES treatment (200 mg/kg Curosurf® administration in 1 hour after birth) or LS treatment (200 mg/kg Curosurf®administration in the first 6 h of life if needed). The patients were treated by nasal continuous positive airway pressure (nCPAP) treatment regardless of the surfactant requirement. Outcomes were the necessity of mechanical ventilation, nCPAP duration, the oxygen requirement duration, the rates of BPD, retinopathy of prematurity (ROP) and mortality, and the assesment of the following situations; (pneumothorax, patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC), and intraventricular hemorrhage (IVH) ≥ grade III). Results: Among 159 infants enrolled in the study, 79 were randomized to ES and 80 to LS treatment groups. Thirty-five patients (44%) in the LS treatment group needed surfactant administration. Necessity of second dose surfactant administration was 8.9% in the ES treatment group. Although necessity of mechanical ventilation, nCPAP duration, oxygen need duration, rates of PDA, NEC, BPD, ROP stage >3 and mortality did not show a significant difference between groups, the ES treatment group had lower rates of pneumothorax and IVH≥ grade III when compared to the LS treatment group. Conclusions: ES treatment decreases IVH (≥ grade III) and pneumothorax rates but does not have any effect on BPD when compared to LS.
  • The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.J Matern Fetal Neonatal Med.2014 Mar;27(4):411-5. doi: 10.3109/14767058.2013.818120. Epub 2013 Jul 30.
  • Abstract Objective: Surfactant treatment in the early hours of life significantly decreases the rates of death and air leak, and increases survival without bronchopulmonary dysplasia (BPD) in preterm infants. We aimed to compare the impact of early surfactant (ES) administration to late selective (L
  • PMID 23795582
  • Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.
  • van Emmerik-van Oortmerssen K, van de Glind G, Koeter MW, Allsop S, Auriacombe M, Barta C, Bu ET, Burren Y, Carpentier PJ, Carruthers S, Casas M, Demetrovics Z, Dom G, Faraone SV, Fatseas M, Franck J, Johnson B, Kapitány-Fövény M, Kaye S, Konstenius M, Levin FR, Moggi F, Møller M, Ramos-Quiroga JA, Schillinger A, Skutle A, Verspreet S; IASP research group, van den Brink W, Schoevers RA.Author information Arkin Mental Health and Addiction Treatment Center, Amsterdam, the Netherlands; Amsterdam Institute for Addiction Research, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.AbstractAIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
  • Addiction (Abingdon, England).Addiction.2014 Feb;109(2):262-72. doi: 10.1111/add.12370. Epub 2013 Nov 20.
  • AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of
  • PMID 24118292

和文文献

  • F6:BPD・DIB(境界性パーソナリティ障害診断面接紙)など (精神科臨床評価検査法マニュアル〔改訂版〕) -- (精神科臨床評価--特定の精神障害に関連したもの)
  • 妊娠の診断と分娩予定日の算出 (周産期診療指針2010) -- (産科編 妊娠の管理・検査)

関連リンク

境界性パーソナリティ障害(きょうかいせいパーソナリティしょうがい、Borderline Personality Disorder,BPD)は、境界型パーソナリティ障害とも呼ばれ、思春期または 成人期に多く生じる、不安定な自己-他者のイメージ、感情・思考の制御の障害、衝動的 な自己 ...

関連画像

borderline-BPD BPD Stats BPD Stigma BPD Diagnosis BPD Mebpd - wordlebpd BPD Awareness Campaign and Educational 5715312051_cb4a812c8f_z.jpgThe biparietal and occipitalfrontal


★リンクテーブル★
先読み境界型人格障害
国試過去問104E051」「105E024」「097B008」「103G009」「099D090」「090A071
リンク元境界性人格障害」「気管支肺異形成症」「妊娠期別検査」「児頭大横径」「頭殿長
拡張検索BPDE
関連記事B」「BP

境界型人格障害」

  [★]

borderline personality disorder unstable personality disorder


104E051」

  [★]


[正答]


※国試ナビ4※ 104E050]←[国試_104]→[104E052

105E024」

  [★]

  • 妊娠中の超音波写真(別冊No.2①~⑤)を別に示す。
  • 児頭大横径(BPD)の計測断面を示しているのはどれか。


  • a ①
  • b ②
  • c ③
  • d ④
  • e ⑤


[正答]


※国試ナビ4※ 105E023]←[国試_105]→[105E025

097B008」

  [★]

  • 正常妊娠の週数と所見の組合せで正しいのはどれか。
  • (1) 5週 - 尿中hCG100,000IU/l
  • (2) 9週 - 頭殿長(CRL)50mm
  • (3) 20週 - 子宮底臍高レベル
  • (4) 30週 - 児体重1,500g
  • (5) 39週 - 児頭大横径(BPD)7.2cm
  • a. (1)(2)
  • b. (1)(5)
  • c. (2)(3)
  • d. (3)(4)
  • e. (4)(5)
[正答]


※国試ナビ4※ 097B007]←[国試_097]→[097B009

103G009」

  [★]

  • 異常所見はどれか。
[正答]


※国試ナビ4※ 103G008]←[国試_103]→[103G010

099D090」

  [★]

  • 妊娠28週の胎児体重推定に用いるのはどれか。
  • a. (1)(2)
  • b. (1)(5)
  • c. (2)(3)
  • d. (3)(4)
  • e. (4)(5)
[正答]


※国試ナビ4※ 099D089]←[国試_099]→[099D091

090A071」

  [★]

  • 胎児について正しいのはどれか?
  • a. 胎動の増減は胎児のwell-beingの評価に有用である
  • b. 胎児の心雑音は電子スキャンにより検出できる
  • c. 胎児の心拍数は妊娠期間を通じてほぼ一定である
  • d. 妊娠後期の頭殿長 CRL子宮内発育遅延の評価に有用である
  • e. 妊娠期間を通じて児頭大横径 BPDは直線的に増大する

境界性人格障害」

  [★]

borderline personality disorder, BPD
人格障害
境界性パーソナリティ障害

DSM-IV

  • 人格障害
  • B群人格障害
  • 境界性人格障害

ICD-10

  • F60-F69 Disorders of adult personality and behaviour
  • F60 Specific personality disorders
  • F60.3 Emotionally unstable personality disorder
  • .30 Impulsive type
  • .31 Borderline type

特徴 (PSY.222)

  • 人格の様々な領域における不安定性と自己の空虚感が目立つ
  • 感情・情動面:挿間的に出現する不快不快感、イライラ、不安が出現する。慢性的な空虚感があり、抑うつ症状を呈することもある。極度の緊張、強い怒りの感情も見られる。
  • 行動面:空虚感や抑うつを伴う感情・情動不安の中で、突然手首切傷や薬を対象に服用した自殺企図、あるいは性的逸脱、薬物乱用、浪費、などが衝動的な後逸形で出現
  • 対人関係面:身近な他社、例えば両親、あるいは多少関係の深まった治療者に対し、しがみつくような形の依存的態度が目立ち、他社との適切な距離がとれない。

疫学 (PSY.222)

  • 有病率:1-2%
  • 女性に多く、男性の2倍
  • 10年以上の経過研究で約2/3の患者が社会適応。9%が自殺。


気管支肺異形成症」

  [★]

bronchopulmonary dysplasia, BPD
気管支肺形成不全症
慢性肺疾患
  • NEL. 737-

概念

  • 新生児特に未熟児の急性、持続性肺障害とそれに対する治療としての人工換気による肺障害が相互に関わった病態。
  • 種々の肺障害によって肺が障害を受け、肺胞と肺の血管の正常な発達が妨げられる。

病因

  • 人工換気において、PEEP不足による肺胞の虚脱、あるいは過剰量の換気による体積負荷、さらには酸素投与にともなって発生するフリーラジカルによる組織障害による。

類似疾患


妊娠期別検査」

  [★]

妊娠
QB.Q-4, G10M.46
  • 妊娠初期
  • 尿中hCG定量:妊娠4週から。予定月経を数日経過してから
超音波検査法:胞状奇胎子宮外妊娠、流産の識別、黄体嚢胞の有無、妊娠週数の推定(GS, CRL)
  • 妊娠中期
  • 妊娠後期
  • 超音波検査法:胎児発育(BPD,FL)、胎盤の位置、羊水の測定(AFI)
  • ノンストレステスト:胎児well-being判定
  • 胎児胎盤機能検査:尿中E3測定、血中CAPhPL測定
  • シェイクテスト:胎児肺成熟度、L/S比

児頭大横径」

  [★]

biparietal diameter, BPD
大横径、胎児児頭大横径
妊娠週数、妊娠期別検査
GS->CRL->BPD
  • NGY.113(発育速度), 336(定義)
  • 第12-15週で妊娠週数の評価に用いられる。
児頭大横径 = 妊娠週数 / 4 (cm)
  • 妊娠末期には9cmとなる。



頭殿長」

  [★]

crown, rump
crown-rump length, CRL
胎児頭殿長
妊娠週数
GS->CRL->BPD
  • 8-11週で分娩日の推定に用いられる。
  • 胎児は丸まっているので、この状態で頭の先から尻の先までを測定する。


BPDE」

  [★] ベンゾピレンジオールエポキシドベンツピレンジオールエポキシド

7,8-dihydro-7,8-dihydroxybenzopyrene-9,10-oxidebenzopyrene diol epoxide


B」

  [★]

  • Mg2+存在下でC3, B, Dが反応してC3bBbとなり、これがC3転換酵素(C3bBb)あるいはC5転換酵素(C3bBb3b)を形成する。これらはP(properdin)と結合して活性化し、それぞれC3、C5を活性化する

WordNet   license wordnet

「the 2nd letter of the Roman alphabet」
b

WordNet   license wordnet

「the blood group whose red cells carry the B antigen」
type B, group B


BP」

  [★]


"http://meddic.jp/BPD" より作成


★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡